# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN-TD
- Date: 1953-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Vasquez-Thornbury, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Restaging after four doses of dostarlimab, and tiredness with cold hands. **S**

## History of present illness

Ms. Didrikson Zaharias comes on the day of her fifth dose, after restaging MRI and sigmoidoscopy last week. The cold she had in early June cleared within a week and she had cycle 4 on time. Over the last month she has become tired again, with cold hands on the course, dry skin and slightly heavier legs; her weight is up 0.8 kg. At the sick visit four weeks ago the TSH was 5.8 mIU/L with a normal free T4. Her bowel movements are normal, with no bleeding, and she has had no diarrhea, rash, cough or breathlessness. Sex is comfortable again. She is playing 18 holes and has entered a club competition next month. **S**

| Element | Detail |
|---|---|
| Treatment | Dostarlimab cycles 1 to 4 on schedule; cycle 5 today |
| Restaging | MRI: near-complete response; sigmoidoscopy: flat scar with a 5 mm shallow ulcer |
| New symptoms | Tiredness, cold hands, dry skin for a month |
| Sport | Playing 18 holes; entered a club competition |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for a month; weight 63.8 kg, up 0.8 kg |
| Integumentary | Positive | Dry skin; no rash |
| Endocrine | Positive | Cold hands; no thirst or headache |
| Gastrointestinal | Negative | Normal bowel movements; no bleeding or diarrhea; mild constipation |
| Respiratory | Negative | Cough gone; no breathlessness |
| Psychiatric | Negative | Pleased with the scans; PHQ-9 3; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth every other morning **S**
- Dostarlimab-gxly 50 mg/mL injection, 500 mg intravenously over 30 minutes every 3 weeks, for nine doses (six months) **S**
- Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 60 bpm; respirations 14/min; temperature 36.4 °C; oxygen saturation 99% on room air; weight 63.8 kg; BMI 22.6 kg/m². All vital signs are synthetic.

Hemoglobin: 13 g/dL; White cell count: 6 10*3/uL; Platelets: 268 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.75 mg/dL; eGFR (CKD-EPI 1948): 102 mL/min/1.73 m²; Glucose: 89 mg/dL; ALT: 20 U/L; AST: 22 U/L; Alkaline phosphatase: 70 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 4.4 g/dL; TSH: 12.6 mIU/L (high); Free T4: 0.6 ng/dL (low); CEA: 2.1 ng/mL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- Hemoglobin: 11 g/dL (low) at baseline, 13 g/dL at this visit **S**
- White cell count: 6.8 10*3/uL at baseline, 6 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 268 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.2 mmol/L at this visit **S**
- Creatinine: 0.78 mg/dL at baseline, 0.75 mg/dL at this visit **S**
- eGFR (CKD-EPI 1948): 98 mL/min/1.73 m² at baseline, 102 mL/min/1.73 m² at this visit **S**
- Glucose: 88 mg/dL at baseline, 89 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 20 U/L at this visit **S**
- AST: 21 U/L at baseline, 22 U/L at this visit **S**
- Alkaline phosphatase: 72 U/L at baseline, 70 U/L at this visit **S**
- Total bilirubin: 0.6 mg/dL at baseline, 0.5 mg/dL at this visit **S**
- Albumin: 4.3 g/dL at baseline, 4.4 g/dL at this visit **S**
- CEA: 5.8 ng/mL (high) at baseline, 2.1 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 63.8 kg; blood pressure 114/72, pulse 60; temperature 36.4 °C |
| Neck | Thyroid not enlarged or tender |
| Skin | Dry skin on the shins; no rash |
| Neurological | Ankle reflexes with slightly slow relaxation |
| Rectal | With her agreement and a chaperone: smooth, with a small firm irregularity at about 4 cm; no mass; no blood |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Low rectal adenocarcinoma, mismatch repair deficient, on dostarlimab** (C20). Near-complete response after four doses: MRI shows fibrosis replacing most of the tumor with a small focus of possible residual tumor at the lower margin and normal-sized nodes; sigmoidoscopy shows a flat scar with a small shallow ulcer; CEA 2.1 ng/mL, now normal. Biopsy of the scar was not taken, since a negative result would not change the plan. Treatment continues to nine doses, as planned, with final restaging after the last dose. **S**
   - Dostarlimab cycle 5 today; cycles 6 to 9 as booked.
   - Final restaging MRI, CT, sigmoidoscopy and examination after cycle 9.
2. **Immune-related primary hypothyroidism, grade 2** (E03.2). TSH 12.6 mIU/L with free T4 0.6 ng/dL, after a mild rise to 5.8 four weeks ago, with tiredness, cold hands, dry skin and a pulse of 60: primary hypothyroidism from immune thyroiditis caused by dostarlimab. The TSH is high, so this is thyroid failure, not pituitary inflammation, and a cortisol test is not needed. Under the ASCO guideline, immunotherapy continues and thyroid hormone is replaced; this kind of hypothyroidism is usually permanent. **S**
   - Levothyroxine 75 micrograms each morning, four hours apart from iron.
   - TSH and free T4 in six weeks.
   - Dostarlimab continues.
3. **Iron deficiency anemia from rectal blood loss** (D50.0). Hemoglobin 13.0 g/dL, now normal, with no bleeding for two months. The ferritin due at three months was not drawn. **S**
   - Continue ferrous sulfate for three months after the hemoglobin became normal.
   - Ferritin with the final restaging blood tests.
4. **Acute viral upper respiratory infection** (J06.9). Resolved within a week; no pneumonitis. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Restaging pelvic MRI and flexible sigmoidoscopy | About every three months during treatment | Up to date | Last week: near-complete response on MRI; flat scar with a 5 mm shallow ulcer on sigmoidoscopy |
| Examination | Digital rectal examination | At each oncology visit during treatment; every three to four months in watch-and-wait | Completed today | Smooth, with a small firm irregularity at about 4 cm; no mass |
| Laboratory | CEA | At diagnosis, at each restaging, then every three to six months for two years | Completed today | 2.1 ng/mL, normal |
| Laboratory | Blood count | Before each dose of dostarlimab and at each visit; about four weeks after oral iron starts | Completed today | Hemoglobin 13.0 g/dL, white cells 6.0, platelets 268 |
| Laboratory | Kidney and liver function and glucose | Before each dose of PD-1 blockade | Completed today | Sodium 140, potassium 4.2 mmol/L; creatinine 0.75 mg/dL, eGFR 102; glucose 89 mg/dL; ALT 20, AST 22, alkaline phosphatase 70 U/L; bilirubin 0.5 mg/dL; albumin 4.4 g/dL |
| Laboratory | TSH and free T4 | At baseline, then every six weeks on PD-1 blockade; six weeks after any levothyroxine change | Completed today | TSH 12.6 mIU/L, free T4 0.6 ng/dL: hypothyroidism; levothyroxine started; TSH checks four and five weeks apart since the last visit |
| Examination | Immune-related adverse event review (diarrhea, rash, cough, breathlessness, fatigue, endocrine symptoms) | Before each dose | Completed today | Hypothyroidism, grade 2; no colitis, rash, pneumonitis or hepatitis |
| Laboratory | Ferritin after oral iron | About three months after starting | Deferred | Missed: the ferritin due about three months after oral iron began was not added to the restaging blood tests. No harm is expected, because the bleeding has stopped and the hemoglobin is normal; corrective action: ferritin added to the final restaging blood tests, and iron continued until then |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and at least yearly | Completed today | PHQ-9 3; item 9 scored 0 |
| Self-management | Sexual health and body image | Through treatment | Completed today | Sex comfortable again since the bleeding stopped |
| Self-management | Physical activity and sport | Each visit | Completed today | Playing 18 holes; entered a club competition |

## Goal progress

- Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment. Outcome by 1953-03-30: Colonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks. **S**
- Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis. Outcome by 1953-04-27: Germline panel negative; two somatic MSH2 variants in the tumor explain the deficiency. **S**
- Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved. In progress; target 1953-10-05. **S**
- Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL. In progress; target 1953-10-05. **S**
- Back to tournament golf during treatment. Outcome by 1953-06-29: Playing 18 holes and entered in a club competition by the fourth visit. **S**
- TSH within the reference range on thyroid replacement. In progress; target 1953-08-10. **S**
- PHQ-9 below 10 throughout treatment. In progress; target 1953-10-05. **S**

## Medication changes

- Started: Levothyroxine 75 microgram oral tablet, one tablet by mouth each morning on an empty stomach, four hours apart from iron **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026), National Comprehensive Cancer Network
- Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022), New England Journal of Medicine
- Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025), New England Journal of Medicine
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026), Aether Forge

## Follow-up

- Dostarlimab cycles 6 to 9 as booked; TSH and free T4 in six weeks; final restaging after cycle 9; preventive visit due. **S**
- Next scheduled visit 1953-08-10: periodic adult preventive visit during immunotherapy. **S**
